Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgillo, Floriana, Della Corte, Carminia Maria, Fasano, Morena, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070275/
https://www.ncbi.nlm.nih.gov/pubmed/27843613
http://dx.doi.org/10.1136/esmoopen-2016-000060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070275/
https://www.ncbi.nlm.nih.gov/pubmed/27843613
http://dx.doi.org/10.1136/esmoopen-2016-000060

Ejemplares similares